Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant interleukin-2

J K Bruton1, J M Koeller

  • 1M.D. Anderson Cancer Center, Houston, Texas.

Pharmacotherapy
|November 1, 1994
PubMed
Summary
This summary is machine-generated.

Recombinant interleukin-2 (IL-2) activates immune cells for cancer treatment, showing promise in renal cell carcinoma and melanoma. Low-dose IL-2 offers comparable efficacy with reduced toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fax technology for collecting outcomes data in a computer database.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1999
Same author

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1999
Same author

Economic analysis of carboplatin versus cisplatin in lung and ovarian cancer.

PharmacoEconomics·1999
Same author

Procedure costs and outcomes associated with pharmacologic management of peripheral arterial disease in the Department of Defense.

Clinical therapeutics·1999
Same author

Clinical guidelines for the treatment of cancer-related anemia.

Pharmacotherapy·1998
Same author

Nutritional parameters observed during 28-day infusion of recombinant human tumor necrosis factor-alpha.

JPEN. Journal of parenteral and enteral nutrition·1993
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
Same journal

Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation.

Pharmacotherapy·2026
Same journal

Quantifying the Serum Magnesium Response and Predictors of Response Following Intravenous Magnesium Replacement in Critically Ill Patients.

Pharmacotherapy·2026
See all related articles

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Recombinant interleukin-2 (IL-2) is an approved immunoregulatory protein.
  • IL-2 acts as a biologic response modifier, activating immune effector cells like T cells, NK cells, and lymphokine-activated killer cells.
  • It lacks direct antitumor activity but mediates cytotoxicity through immune cell activation.

Purpose of the Study:

  • To review the immunologic effects and clinical activity of recombinant IL-2.
  • To discuss the efficacy and toxicity profile of high-dose and low-dose IL-2 therapy.
  • To evaluate the potential of low-dose IL-2 as a safer alternative.

Main Methods:

  • Review of existing literature on recombinant IL-2.
  • Analysis of clinical trial data for renal cell carcinoma and melanoma.

Related Experiment Videos

  • Comparison of response rates and toxicity between high-dose and low-dose IL-2 regimens.

    • Main Results:

    • Recombinant IL-2 demonstrated objective response rates of 15-20% in renal cell carcinoma and melanoma.
    • Median duration of response in renal cell carcinoma was 23 months.
    • High-dose IL-2 is associated with significant toxicities including hypertension, weight gain, and neurotoxicity, which are generally reversible.
    • Low-dose IL-2 administration significantly reduces toxicity.
    • Response rates to low-dose IL-2 appear comparable to high-dose IL-2, particularly in renal cell carcinoma.

    Conclusions:

    • Recombinant IL-2 is an effective immunomodulator for treating certain cancers like renal cell carcinoma and melanoma.
    • While high-dose IL-2 shows efficacy, its significant toxicity necessitates careful management.
    • Low-dose IL-2 presents a promising strategy to mitigate toxicity while maintaining comparable therapeutic benefits, especially in renal cell carcinoma.